The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases

Expert Review of Clinical Immunology

Volumn 10, Issue 5, 2014, Pages 593-619

  Russo, Remo C ^a   Garcia, Cristiana C ^a   Teixeira, Mauro M ^a   Amaral, Flavio A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

acute and chronic inflammation; chemoattractants; clinical trials; CXCL8; CXCR1; CXCR2; infection

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; ABX IL 8; ABX IL8; ANTILEUKINATE; AZD 4721; AZD 5069; AZD 8309; CHEMOKINE; CHEMOKINE CXCL7; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; DANIRIXIN; DF 2156A; ELUBRIXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; MONOCLONAL ANTIBODY CXCL8; NAVARIXIN; PA 401; PROTON PUMP INHIBITOR; REPARIXIN; SB 332235; SB 468477; UNCLASSIFIED DRUG; 2-HYDROXY-N,N-DIMETHYL-3-(2-((1-(5-METHYLFURAN-2-YL)PROPYL)AMINO)-3,4-DIOXOCYCLOBUT-1-ENYLAMINO)BENZAMIDE; ABX-INTERLEUKIN 8; BENZAMIDE DERIVATIVE; CYCLOBUTANE DERIVATIVE; MONOCLONAL ANTIBODY;

ACUTE LUNG INJURY; ANGIOGENESIS; ASTHMA; ATHEROSCLEROSIS; BREAST CANCER; BRONCHIECTASIS; BULLOUS PEMPHIGOID; CARCINOGENESIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMPHYSEMA; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROBLAST; FIBROSIS; GRAFT DYSFUNCTION; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; LUNG FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NERVE CELL; NEUTROPHIL; NONHUMAN; ORGAN TRANSPLANTATION; PAIN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SINGLE DRUG DOSE; TISSUE INJURY; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; NEUTROPHIL CHEMOTAXIS;

ANTIBODIES, MONOCLONAL; BENZAMIDES; CYCLOBUTANES; HUMANS; INFLAMMATION; INTERLEUKIN-8; MODELS, BIOLOGICAL; NEUTROPHIL INFILTRATION; NEUTROPHILS; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B;

EID: 84898875335     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.894886     Document Type: Review

References (282)

1. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338(7):436-45
2. Russo RC, Garcia CC, Teixeira MM. Anti-inflammatory drug development: broad or specific chemokine receptor antagonists? Curr Opin Drug Discov Devel 2010;13(4): 414-27
3. Bachelerie F, Ben-Baruch A, Burkhardt AM, et al. International union of pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 2013;66(1): 1-79
4. Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med 1999;50:425-40
5. Thelen M, Stein JV. How chemokines invite leukocytes to dance. Nat Immunol 2008;9(9):953-9
6. Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987; 149(2):755-61
7. Schroder JM, Mrowietz U, Morita E, Christophers E. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol 1987;139(10):3474-83
8. Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987;84(24):9233-7
9. Balkwill FR, Burke F. The cytokine network. Immunol Today 1989;10(9): 299-304
10. Ahuja SK, Shetty A, Tiffany HL, Murphy PM. Comparison of the genomic organization and promoter function for human interleukin-8 receptors A and B. J Biol Chem 1994;269(42): 26381-9
11. Ahuja SK, Ozcelik T, Milatovitch A, et al. Molecular evolution of the human interleukin-8 receptor gene cluster. Nat Genet 1992;2(1):31-6
12. Mollereau C, Muscatelli F, Mattei MG, et al. The high-affinity interleukin 8 receptor gene (IL8RA) maps to the 2q33-q36 region of the human genome: cloning of a pseudogene (IL8RBP) for the low-affinity receptor. Genomics 1993;16(1): 248-51
13. Wolf M, Delgado MB, Jones SA, et al. Granulocyte chemotactic protein 2 acts via both IL-8 receptors, CXCR1 and CXCR2. Eur J Immunol 1998;28(1):164-70
14. Stillie R, Farooq SM, Gordon JR, Stadnyk AW. The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol 2009;86(3): 529-43
15. Murphy PM. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol 1997;34(4):311-18
16. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994;12:593-633
17. Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006;12(3):317-23
18. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008;180(8):5662-9
19. Weber C, Kraemer S, Drechsler M, et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 2008;105(42):16278-83
20. Schober A, Bernhagen J, Weber C. Chemokine-like functions of MIF in atherosclerosis. J Mol Med (Berl) 2008; 86(7):761-70
21. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007;13(5): 587-96
22. Yoshimura T, Matsushima K, Oppenheim JJ, Leonard EJ. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J Immunol 1987; 139(3):788-93
23. Strieter RM, Kunkel SL, Showell HJ, Marks RM. Monokine-induced gene expression of a human endothelial cell-derived neutrophil chemotactic factor. Biochem Biophys Res Commun 1988; 156(3):1340-5
24. Strieter RM, Kunkel SL, Showell HJ, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science 1989;243(4897):1467-9
25. Gregory H, Young J, Schroder JM, et al. Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP). Biochem Biophys Res Commun 1988;151(2):883-90
26. Schroder JM, Mrowietz U, Christophers E. Purification and partial biologic characterization of a human lymphocyte-derived peptide with potent neutrophil-stimulating activity. J Immunol 1988;140(10):3534-40
27. Schroder JM, Sticherling M, Henneicke HH, et al. IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. J Immunol 1990;144(6): 2223-32
28. Proost P, De Wolf-Peeters C, Conings R, et al. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J Immunol 1993;150(3):1000-10
29. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 1992;307(1):97-101
30. Wettey FR, Xue L, Pettipher R. Salbutamol inhibits trypsin-mediated production of CXCL8 by keratinocytes. Cytokine 2006; 36(1-2):29-34
31. Bonecchi R, Facchetti F, Dusi S, et al. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol 2000;164(7):3862-9
32. Hess C, Means TK, Autissier P, et al. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood 2004;104(12): 3463-71
33. Takata H, Naruto T, Takiguchi M. Functional heterogeneity of human effector CD8+ T cells. Blood 2012;119(6):1390-8
34. Nilsson G, Mikovits JA, Metcalfe DD, Taub DD. Mast cell migratory response to interleukin-8 is mediated through interaction with chemokine receptor CXCR2/Interleukin-8RB. Blood 1999; 93(9):2791-7
35. Ochensberger B, Tassera L, Bifrare D, et al. Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agonists. Eur J Immunol 1999; 29(1):11-22
36. Thomas SY, Hou R, Boyson JE, et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 2003;171(5):2571-80
37. Katoh H, Wang D, Daikoku T, et al. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013;24(5):631-44
38. Loetscher P, Seitz M, Clark-Lewis I, et al. Both interleukin-8 receptors independently mediate chemotaxis. Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO alpha and NAP-2. FEBS Lett 1994;341(2-3):187-92
39. Hammond ME, Lapointe GR, Feucht PH, et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 1995;155(3):1428-33
40. Jones SA, Wolf M, Qin S, et al. Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2. Proc Natl Acad Sci USA 1996;93(13): 6682-6
41. Kondo S, Yoneta A, Yazawa H, et al. Downregulation of CXCR-2 but not CXCR-1 expression by human keratinocytes by UVB. J Cell Physiol 2000;182(3):366-70
42. Nirodi CS, Devalaraja R, Nanney LB, et al. Chemokine and chemokine receptor expression in keloid and normal fibroblasts. Wound Repair Regen 2000;8(5):371-82
43. Horuk R, Martin AW, Wang Z, et al. Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol 1997;158(6):2882-90
44. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995;4(3): 155-60
45. Sturm A, Baumgart DC, d'Heureuse JH, et al. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 2005;29(1):42-8
46. Al-Alwan LA, Chang Y, Mogas A, et al. Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration. J Immunol 2013;191(5): 2731-41
47. Clarke C, Kuboki S, Sakai N, et al. CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia/reperfusion injury. Hepatology 2011;53(1):261-71
48. Horton LW, Yu Y, Zaja-Milatovic S, et al. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res 2007; 67(20):9791-9
49. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258(5089):1798-801
50. Strieter RM, Polverini PJ, Arenberg DA, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995;57(5):752-62
51. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270(45):27348-57
52. Bertini R, Barcelos LS, Beccari AR, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. Br J Pharmacol 2012;165(2):436-54
53. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008;28(11): 1897-908
54. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010;17(4):332-41
55. Satterthwaite G, Francis SE, Suvarna K, et al. Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. Am Heart J 2005;150(3):488-99
56. Breland UM, Halvorsen B, Hol J, et al. A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol 2008;28(5): 1005-11
57. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101(2):353-63
58. Soehnlein O, Drechsler M, Doring Y, et al. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med 2013;5(3):471-81
59. van Tits LJ, Stienstra R, van Lent PL, et al. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011; 214(2):345-9
60. Wang F, Xia W, Liu F et al. Interferon regulator factor 1/retinoic inducible gene I (IRF1/RIG-I) axis mediates 25-hydroxycholesterol-induced interleukin-8 production in atherosclerosis. Cardiovasc Res 2012;93(1):190-9
61. Demetz G, Seitz I, Stein A, et al. Tissue factor-factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells. Atherosclerosis 2010;212(2):466-71
62. Drechsler M, Megens RT, van Zandvoort M, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010;122(18): 1837-45
63. Qin Y, Fan F, Zhao Y, et al. Recombinant human CXCL8(3-72)K11R/G31P regulates smooth muscle cell proliferation and migration through blockage of interleukin-8 receptor. IUBMB Life 2013;65(1):67-75
64. Hol J, Otterdal K, Breland UM, et al. Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies. PLoS One 2012;7(7):e40673
65. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14(21):6735-41
66. Luan J, Shattuck-Brandt R, Haghnegahdar H, et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997;62(5):588-97
67. Yoneda J, Kuniyasu H, Crispens MA, et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90(6): 447-54
68. Keane MP, Belperio JA, Xue YY, et al. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004;172(5):2853-60
69. Keane MP, Burdick MD, Xue YY, et al. The chemokine receptor, CXCR2, mediates the tumorigenic effects of ELR+ CXC chemokines. Chest 2004;125(5 Suppl):133S
70. Bostwick DG, Iczkowski KA. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 1998; 16(3):118-23
71. Fregene TA, Khanuja PS, Noto AC, et al. Tumor-associated angiogenesis in prostate cancer. Anticancer Res 1993;13(6B): 2377-81
72. Moore BB, Arenberg DA, Stoy K, et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999;154(5):1503-12
73. Luca M, Huang S, Gershenwald JE, et al. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997;151(4):1105-13
74. Kitadai Y, Haruma K, Sumii K, et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998;152(1):93-100
75. Miller LJ, Kurtzman SH, Wang Y, et al. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 1998;18(1A):77-81
76. Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994;54(12):3242-7
77. Richards BL, Eisma RJ, Spiro JD, et al. Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma. Am J Surg 1997;174(5):507-12
78. Addison CL, Belperio JA, Burdick MD, Strieter RM. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 2004;4:28
79. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391(6662):86-9
80. Burger M, Burger JA, Hoch RC, et al. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J Immunol 1999;163(4):2017-22
81. Gershengorn MC, Geras-Raaka E, Varma A, Clark-Lewis I. Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J Clin Invest 1998;102(8): 1469-72
82. Cortez-Retamozo V, Etzrodt M, Newton A, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA 2012;109(7):2491-6
83. Wang R, Zhang T, Ma Z, et al. The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer. Gynecol Oncol 2010;117(3):460-6
84. Mohamed MM, El-Ghonaimy EA, Nouh MA, et al. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol 2014;46:138-47
85. Medina RJ, O'Neill CL, O'Doherty TM, et al. Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol Med 2011;17(9-10):1045-55
86. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004;10(15): 4895-900
87. Mishalian I, Bayuh R, Levy L, et al. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother 2013;62(11):1745-56
88. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16(3):183-94
89. Shang K, Bai YP, Wang C, et al. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS One 2012; 7(12):e51848
90. Liang-Kuan B, Nan Z, Cheng L, et al. Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells. Urol Oncol 2014; Epub ahead of print
91. Singh JK, Farnie G, Bundred NJ, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res 2013;19(3): 643-56
92. Li A, Cheng XJ, Moro A, et al. CXCR2-Dependent Endothelial Progenitor Cell Mobilization in Pancreatic Cancer Growth. Transl Oncol 2011;4(1): 20-8
93. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008;8(6): 458-66
94. Williams EJ, Haque S, Banks C, et al. Distribution of the interleukin-8 receptors, CXCR1 and CXCR2, in inflamed gut tissue. J Pathol 2000;192(4):533-9
95. Autschbach F, Funke B, Katzenmeier M, Gassler N. Expression of chemokine receptors in normal and inflamed human intestine, tonsil, and liver-an immunohistochemical analysis with new monoclonal antibodies from the 8th international workshop and conference on human leucocyte differentiation antigens. Cell Immunol 2005;236(1-2):110-14
96. Banks C, Bateman A, Payne R, et al. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003;199(1):28-35
97. Nguyen-Jackson H, Panopoulos AD, Zhang H, et al. STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction. Blood 2010;115(16):3354-63
98. Willson TA, Kuhn BR, Jurickova I, et al. STAT3 genotypic variation and cellular STAT3 activation and colon leukocyte recruitment in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012;55(1): 32-43
99. Buanne P, Di Carlo E, Caputi L, et al. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol 2007;82(5):1239-46
100. Bento AF, Leite DF, Claudino RF, et al. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol 2008;84(4): 1213-21
101. Farooq SM, Stillie R, Svensson M, et al. Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther 2009;329(1):123-9
102. Koelink PJ, Overbeek SA, Braber S, et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 2013; Epub ahead of print
103. Lebeis SL, Bommarius B, Parkos CA, et al. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J Immunol 2007;179(1):566-77
104. Spehlmann ME, Dann SM, Hruz P, et al. CXCR2-dependent mucosal neutrophil influx protects against colitis-associated diarrhea caused by an attaching/effacing lesion-forming bacterial pathogen. J Immunol 2009;183(5):3332-43
105. Zindl CL, Lai JF, Lee YK, et al. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc Natl Acad Sci USA 2013;110(31): 12768-73
106. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361(21): 2066-78
107. Jamieson T, Clarke M, Steele CW, et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 2012;122(9): 3127-44
108. Asfaha S, Dubeykovskiy AN, Tomita H, et al. Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology 2013; 144(1):155-66
109. Herbold W, Maus R, Hahn I, et al. Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect Immun 2010;78(6):2620-30
110. Mehrad B, Strieter RM, Moore TA, et al. CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J Immunol 1999; 163(11):6086-94
111. Del Rio L, Bennouna S, Salinas J, Denkers EY. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J Immunol 2001;167(11): 6503-9
112. Eisele NA, Lee-Lewis H, Besch-Williford C, et al. Chemokine receptor CXCR2 mediates bacterial clearance rather than neutrophil recruitment in a murine model of pneumonic plague. Am J Pathol 2011; 178(3):1190-200
113. Schuh JM, Blease K, Hogaboam CM. CXCR2 is necessary for the development and persistence of chronic fungal asthma in mice. J Immunol 2002;168(3):1447-56
114. Weinger JG, Marro BS, Hosking MP, Lane TE. The chemokine receptor CXCR2 and coronavirus-induced neurologic disease. Virology 2013;435(1):110-17
115. Luttichau HR The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist. J Biol Chem 2010; 285( 12): 9137-46
116. Nagarkar DR, Wang Q, Shim J, et al. CXCR2 is required for neutrophilic airway inflammation and hyperresponsiveness in a mouse model of human rhinovirus infection. J Immunol 2009;183(10): 6698-707
117. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369(21):2063
118. Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007;11(2):R49
119. Alves-Filho JC, de Freitas A, Spiller F, et al. The role of neutrophils in severe sepsis. Shock 2008;30(Suppl 1):3-9
120. Drifte G, Dunn-Siegrist I, Tissieres P, Pugin J. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit Care Med 2013;41(3): 820-32
121. Guo F, Tang J, Zhou Z, et al. GEF-H1-RhoA signaling pathway mediates LPS-induced NF-kappaB transactivation and IL-8 synthesis in endothelial cells. Mol Immunol 2012;50(1-2):98-107
122. Schildberger A, Rossmanith E, Weber V, Falkenhagen D. Monitoring of endothelial cell activation in experimental sepsis with a two-step cell culture model. Innate Immun 2010;16(5):278-87
123. Wang L, Han G, Wang R, et al. Regulation of IL-8 production by complement-activated product, C5a, in vitro and in vivo during sepsis. Clin Immunol 2010;137(1):157-65
124. Cummings CJ, Martin TR, Frevert CW, et al. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J Immunol 1999;162(4): 2341-6
125. Tikhonov I, Doroshenko T, Chaly Y, et al. Down-regulation of CXCR1 and CXCR2 expression on human neutrophils upon activation of whole blood by S. aureus is mediated by TNF-alpha. Clin Exp Immunol 2001;125(3):414-22
126. Rios-Santos F, Alves-Filho JC, Souto FO, et al. Down-regulation of CXCR2 on neutrophils in severe sepsis is mediated by inducible nitric oxide synthase-derived nitric oxide. Am J Respir Crit Care Med 2007; 175(5):490-7
127. Alves-Filho JC, Freitas A, Souto FO, et al. Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis. Proc Natl Acad Sci USA 2009; 106(10):4018-23
128. Czaikoski PG, Nascimento DC, Sonego F, et al. Heme oxygenase inhibition enhances neutrophil migration into the bronchoalveolar spaces and improves the outcome of murine pneumonia-induced sepsis. Shock 2013;39(4):389-96
129. Goodman R, Cummings C, Frevert C, et al. Functional significance of CXCR2 downregulation on neutrophils from patients with severe sepsis. Chest 1999;116(1 Suppl):111S-2S
130. Pinho V, Russo RC, Amaral FA, et al. Tissue- and stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo. J Immunol 2007; 179(11):7891-8
131. Martin EL, Souza DG, Fagundes CT, et al. Phosphoinositide-3 kinase gamma activity contributes to sepsis and organ damage by altering neutrophil recruitment. Am J Respir Crit Care Med 2010;182(6):762-73
132. Alves-Filho JC, Sonego F, Souto FO, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010;16(6):708-12
133. Feterowski C, Mack M, Weighardt H, et al. CC chemokine receptor 2 regulates leukocyte recruitment and IL-10 production during acute polymicrobial sepsis. Eur J Immunol 2004;34(12):3664-73
134. Speyer CL, Gao H, Rancilio NJ, et al. Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol 2004;165(6):2187-96
135. Souto FO, Alves-Filho JC, Turato WM, et al. Essential role of CCR2 in neutrophil tissue infiltration and multiple organ dysfunction in sepsis. Am J Respir Crit Care Med 2011;183(2):234-42
136. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000; 190(3):255-66
137. Metinko AP, Kunkel SL, Standiford TJ, Strieter RM. Anoxia-hyperoxia induces monocyte-derived interleukin-8. J Clin Invest 1992;90(3):791-8
138. Souza DG, Bertini R, Vieira AT, et al. Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 2004;143(1):132-42
139. Montecucco F, Bauer I, Braunersreuther V, et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal 2013; 18(6):630-41
140. Garau A, Bertini R, Mosca M, et al. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. Eur Cytokine Netw 2006;17(1):35-41
141. Souza DG, Teixeira MM. The balance between the production of tumor necrosis factor-alpha and interleukin-10 determines tissue injury and lethality during intestinal ischemia and reperfusion. Mem Inst Oswaldo Cruz 2005;100(Suppl 1): 59-66
142. Popivanova BK, Koike K, Tonchev AB, et al. Accumulation of microglial cells expressing ELR motif-positive CXC chemokines and their receptor CXCR2 in monkey hippocampus after ischemia-reperfusion. Brain Res 2003;970(1-2): 195-204
143. Kuboki S, Shin T, Huber N, et al. Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice. Hepatology 2008;48(4):1213-23
144. Van Sweringen HL, Sakai N, Quillin RC, et al. Roles of hepatocyte and myeloid CXC chemokine receptor-2 in liver recovery and regeneration after ischemia/reperfusion in mice. Hepatology 2013;57(1):331-8
145. Bhatia M, Zemans RL, Jeyaseelan S. Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol 2012;46(5):566-72
146. Gonzalez-Lopez A, Albaiceta GM. Repair after acute lung injury: molecular mechanisms and therapeutic opportunities. Crit Care 2012;16(2):209
147. Konrad FM, Reutershan J. CXCR2 in acute lung injury. Mediators Inflamm 2012;2012:740987
148. Steinberg KP, Milberg JA, Martin TR, et al. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994;150(1):113-22
149. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154(3 Pt 1):602-11
150. Donnelly SC, Strieter RM, Kunkel SL, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993;341(8846): 643-7
151. Aggarwal A, Baker CS, Evans TW, Haslam PL. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J 2000;15(5): 895-901
152. Kurdowska A, Noble JM, Grant IS, et al. Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Crit Care Med 2002;30(10): 2335-7
153. Fudala R, Krupa A, Matthay MA, et al. Anti-IL-8 autoantibody: IL-8 immune complexes suppress spontaneous apoptosis of neutrophils. Am J Physiol Lung Cell Mol Physiol 2007;293(2):L364-74
154. Mei J, Liu Y, Dai N, et al. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity 2010;33(1):106-17
155. Kangelaris KN, Sapru A, Calfee CS, et al. The association between a Darc gene polymorphism and clinical outcomes in African American patients with acute lung injury. Chest 2012;141(5):1160-9
156. Zarbock A, Bishop J, Muller H, et al. Chemokine homeostasis vs. chemokine presentation during severe acute lung injury: the other side of the Duffy antigen receptor for chemokines. Am J Physiol Lung Cell Mol Physiol 2010;298(3):L462-71
157. Zarbock A, Allegretti M, Ley K. Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice. Br J Pharmacol 2008;155(3):357-64
158. Bhatia M, Hegde A. Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice against acute pancreatitis and associated lung injury. Regul Pept 2007;138(1):40-8
159. Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J Clin Invest 2002;110(11):1703-16
160. Sue RD, Belperio JA, Burdick MD, et al. CXCR2 is critical to hyperoxia-induced lung injury. J Immunol 2004;172(6):3860-8
161. Reutershan J, Morris MA, Burcin TL, et al. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. J Clin Invest 2006;116(3):695-702
162. Lazaar AL, Sweeney LE, MacDonald AJ, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011;72(2):282-93
163. Holz O, Khalilieh S, Ludwig-Sengpiel A, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010;35(3):564-70
164. Virtala R, Ekman AK, Jansson L, et al. Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. Clin Exp Allergy 2012;42(4): 590-6
165. Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. Front Microbiol 2013;4:263
166. Lamblin C, Gosset P, Tillie-Leblond I, et al. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med 1998;157(2): 394-402
167. Kurashima K, Mukaida N, Fujimura M, et al. Increase of chemokine levels in sputum precedes exacerbation of acute asthma attacks. J Leukoc Biol 1996;59(3): 313-16
168. Qiu Y, Zhu J, Bandi V, et al. Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax 2007;62(6):475-82
169. Fujimura M, Myou S, Nomura M, et al. Interleukin-8 inhalation directly provokes bronchoconstriction in guinea pigs. Allergy 1999;54(4):386-91
170. Govindaraju V, Michoud MC, Al-Chalabi M, et al. Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration. Am J Physiol Cell Physiol 2006;291(5): C957-65
171. De Sanctis GT, MacLean JA, Qin S, et al. Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation. J Clin Invest 1999;103(4): 507-15
172. Jones CP, Pitchford SC, Lloyd CM, Rankin SM. CXCR2 mediates the recruitment of endothelial progenitor cells during allergic airways remodeling. Stem Cells 2009;27(12):3074-81
173. Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012;42(7): 1097-103
174. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012;122(8):2749-55
175. Traves SL, Smith SJ, Barnes PJ, Donnelly LE. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 2004;76(2):441-50
176. Stevenson CS, Coote K, Webster R, et al. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol 2005; 288(3):L514-22
177. Thatcher TH, McHugh NA, Egan RW, et al. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 2005; 289(2):L322-8
178. Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med 2012;10:88
179. Richman-Eisenstat JB, Jorens PG, Hebert CA, et al. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993;264(4 Pt 1): L413-18
180. Govindaraju V, Michoud MC, Ferraro P, et al. The effects of interleukin-8 on airway smooth muscle contraction in cystic fibrosis. Respir Res 2008;9:76
181. Kormann MS, Hector A, Marcos V, et al. CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease. Eur Respir J 2012;39(6):1385-90
182. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007;13(12):1423-30
183. Marcos V, Zhou Z, Yildirim AO, et al. CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat Med 2010;16(9): 1018-23
184. Marcos V, Zhou Z, Yildirim AO, et al. Retraction: CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat Med 2011;17(7):899
185. Moss RB, Mistry SJ, Konstan MW, et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2013; 12(3):241-8
186. Tsai WC, Strieter RM, Mehrad B, et al. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 2000;68(7): 4289-96
187. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009;2(2):103-21
188. Carre PC, Mortenson RL, King TE Jr, et al. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest 1991;88(6):1802-10
189. Car BD, Meloni F, Luisetti M, et al. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 1994;149(3 Pt 1):655-9
190. Giri SN, Schwartz LW, Hollinger MA, et al. Biochemical and structural alterations of hamster lungs in response to intratracheal administration of bleomycin. Exp Mol Pathol 1980;33(1):1-14
191. Russo RC, Guabiraba R, Garcia CC, et al. Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2009;40(4):410-21
192. Keane MP, Belperio JA, Moore TA, et al. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999;162(9):5511-18
193. Besnard AG, Struyf S, Guabiraba R, et al. CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model. J Leukoc Biol 2013; 94(6):1317-23
194. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294(2):L152-60
195. Asensio VC, Campbell IL. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci 1999;22(11): 504-12
196. Rostene W, Kitabgi P, Parsadaniantz SM. Chemokines: a new class of neuromodulator? Nat Rev Neurosci 2007; 8(11):895-903
197. Kingwell K. Multiple sclerosis: putting a dampener on inflammation. Nat Rev Drug Discov 2010;9(9):679
198. Roy M, Richard JF, Dumas A, Vallieres L. CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis. J Neuroinflammation 2012;9:18
199. Carlson T, Kroenke M, Rao P, et al. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 2008;205(4):811-23
200. Nguyen D, Stangel M. Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Brain Res Dev Brain Res 2001;128(1):77-81
201. Omari KM, John G, Lango R, Raine CS. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006;53(1):24-31
202. Lindner M, Trebst C, Heine S, et al. The chemokine receptor CXCR2 is differentially regulated on glial cells in vivo but is not required for successful remyelination after cuprizone-induced demyelination. Glia, 2008;56(10):1104-13
203. Omari KM, Lutz SE, Santambrogio L, et al. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1. Am J Pathol 2009; 174(1):164-76
204. Tirotta E, Ransohoff RM, Lane TE. CXCR2 signaling protects oligodendrocyte progenitor cells from IFN-gamma/CXCL10-mediated apoptosis. Glia 2011;59(10): 1518-28
205. Ro H, Hwang YH, Kim H, et al. Association of polymorphisms of interleukin-8, CXCR1, CXCR2, and selectin with allograft outcomes in kidney transplantation. Transplantation 2011;91(1): 57-64
206. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003;284(1):G15-26
207. Krohn N, Kapoor S, Enami Y, et al. Hepatocyte transplantation-induced liver inflammation is driven by cytokines-chemokines associated with neutrophils and Kupffer cells. Gastroenterology 2009;136(5): 1806-17
208. Belperio JA, Keane MP, Burdick MD, et al. CXCR2/CXCR2 ligand biology during lung transplant ischemia-reperfusion injury. J Immunol 2005;175(10):6931-9
209. Citro A, Cantarelli E, Maffi P, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest 2012;122(10):3647-51
210. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009;139(2): 267-84
211. Cunha TM, Verri WA Jr, Silva JS, et al. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci USA 2005;102(5): 1755-60
212. Zhang ZJ, Cao DL, Zhang X, et al. Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain 2013;154(10):2185-97
213. Brack A, Rittner HL, Machelska H, et al. Control of inflammatory pain by chemokine-mediated recruitment of opioid-containing polymorphonuclear cells. Pain 2004;112(3):229-38
214. Rittner HL, Labuz D, Schaefer M, et al. Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells. FASEB J 2006;20(14):2627-9
215. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity 2011;35(6): 857-69
216. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445(7130):866-73
217. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010; 29(1):3-9
218. Schulz BS, Michel G, Wagner S, et al. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 1993;151(8): 4399-406
219. Kulke R, Bornscheuer E, Schluter C, et al. The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 1998; 110(1):90-4
220. Reich K, Garbe C, Blaschke V, et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001;116(2): 319-29
221. Bruch-Gerharz D, Fehsel K, Suschek C, et al. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 1996;184(5):2007-12
222. Duan H, Koga T, Kohda F, et al. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 2001;26(2): 119-24
223. Nickoloff BJ, Mitra RS, Varani J, et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144(4):820-8
224. Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009; 90(3):232-48
225. Watanabe H, Kawaguchi M, Fujishima S, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol 2009;129(3): 650-6
226. Guilloteau K, Paris I, Pedretti N, et al. Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1{alpha}, and TNF-{alpha} Recapitulates Some Features of Psoriasis. J Immunol 2010; Epub ahead of print
227. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2(52):52ra72
228. Hueber AJ, Alves-Filho JC, Asquith DL, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 2011;41(8):2229-37
229. Dinarello C, Arend W, Sims J, et al. IL-1 family nomenclature. Nat Immunol 2010;11(11):973
230. Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 2007;204(11): 2603-14
231. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 2011;131(12): 2428-37
232. Joyce CE, Zhou X, Xia J, et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet 2011;20(20): 4025-40
233. Xu N, Meisgen F, Butler LM, et al. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40. J Immunol 2013;190(2):678-88
234. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011;13(Suppl 1):S5
235. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373(9664):659-72
236. Kraan MC, Patel DD, Haringman JJ, et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res 2001;3(1):65-71
237. Troughton PR, Platt R, Bird H, et al. Synovial fluid interleukin-8 and neutrophil function in rheumatoid arthritis and seronegative polyarthritis. Br J Rheumatol 1996;35(12):1244-51
238. Andreas K, Lubke C, Haupl T, et al. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther 2008;10(1):R9
239. Patterson AM, Gardner L, Shaw J, et al. Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. Arthritis Rheum 2005;52(8): 2331-42
240. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43(1):38-47
241. Hirota K, Akahoshi T, Endo H, et al. Production of interleukin 8 by cultured synovial cells in response to interleukin 1 and tumor necrosis factor. Rheumatol Int 1992;12(1):13-16
242. Seitz M, Dewald B, Gerber N, Baggiolini M. Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin Invest 1991;87(2):463-9
243. Schmidt EM, Davies M, Mistry P, et al. Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. Arthritis Rheum 2013;65(9): 2262-73
244. Loetscher P, Dewald B, Baggiolini M, Seitz M. Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. Cytokine 1994;6(2): 162-70
245. Coelho FM, Pinho V, Amaral FA, et al. The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. Arthritis Rheum 2008;58(8):2329-37
246. Grespan R, Fukada SY, Lemos HP, et al. CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum 2008;58(7):2030-40
247. Sachs D, Coelho FM, Costa VV, et al. Cooperative role of tumour necrosis factor-alpha, interleukin-1beta and neutrophils in a novel behavioural model that concomitantly demonstrates articular inflammation and hypernociception in mice. Br J Pharmacol 2011;162(1):72-83
248. Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006;21(5):557-66
249. Kasama T, Kobayashi K, Yajima N, et al. Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin Exp Immunol 2000;121(3):533-8
250. Kasama T, Shiozawa F, Kobayashi K, et al. Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts. Arthritis Rheum 2001;44(11):2512-24
251. Reich N, Beyer C, Gelse K, et al. Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J Cell Mol Med 2011; 15(4):756-62
252. Haas CS, Amin MA, Ruth JH, et al. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 2007;56(8):2535-48
253. Segerer S, Henger A, Schmid H, et al. Expression of the chemokine receptor CXCR1 in human glomerular diseases. Kidney Int 2006;69(10):1765-73
254. Araki M, Fahmy N, Zhou L, et al. Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. Transplantation 2006;81(5):783-8
255. Cugini D, Azzollini N, Gagliardini E, et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005;67(5):1753-61
256. Neri F, Puviani L, Tsivian M, et al. Protective effect of an inhibitor of interleukin-8 (meraxin) from ischemia and reperfusion injury in a rat model of kidney transplantation. Transplant Proc 2007; 39(6):1771-2
257. Bedke J, Nelson PJ, Kiss E, et al. A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Mol Immunol 2010;47(5):1047-57
258. Sheu JN, Chen SM, Meng MH, Lue KH. The role of serum and urine interleukin-8 on acute pyelonephritis and subsequent renal scarring in children. Pediatr Infect Dis J 2009;28(10):885-90
259. Huang F, Horikoshi S, Kurusu A, et al. Urinary levels of interleukin-8 (IL-8) and disease activity in patients with IgA nephropathy. J Clin Lab Anal 2001; 15(1):30-4
260. Souto MF, Teixeira AL, Russo RC, et al. Immune mediators in idiopathic nephrotic syndrome: evidence for a relation between interleukin 8 and proteinuria. Pediatr Res 2008;64(6):637-42
261. Zernecke A, Weber KS, Erwig LP, et al. Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol 2001;166(9):5755-62
262. Wada T, Tomosugi N, Naito T, et al. Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental acute immune complex-induced glomerulonephritis. J Exp Med 1994;180(3):1135-40
263. Ranganathan P, Jayakumar C, Manicassamy S, Ramesh G. CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation. Am J Physiol Renal Physiol 2013;305(10):F1422-7
264. Tabel Y, Mir S, Berdeli A. Interleukin 8 gene 2767 A/G polymorphism is associated with increased risk of nephritis in children with Henoch-Schonlein purpura. Rheumatol Int 2012;32(4):941-7
265. Rovin BH, Lu L, Zhang X. A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. Kidney Int 2002;62(1): 261-5
266. Urquidi V, Chang M, Dai Y, et al. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol 2012;12:12
267. Lotti F, Maggi M. Interleukin 8 and the male genital tract. J Reprod Immunol 2013; 100(1):54-65
268. Liu L, Li Q, Han P, et al. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology 2009; 74(2):340-4
269. Penna G, Fibbi B, Amuchastegui S, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009;182(7):4056-64
270. Castro P, Xia C, Gomez L, et al. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004;60(2): 153-9
271. Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007;51(2):524-33; discussion 533
272. Shimoya K, Matsuzaki N, Tsutsui T, et al. Detection of interleukin-8 (IL-8) in seminal plasma and elevated IL-8 in seminal plasma of infertile patients with leukospermia. Fertil Steril 1993;59(4):885-8
273. Carmona F, Chapron C, Martinez-Zamora MA, et al. Ovarian endometrioma but not deep infiltrating endometriosis is associated with increased serum levels of interleukin-8 and interleukin-6. J Reprod Immunol 2012; 95(1-2):80-6
274. Milewski L, Dziunycz P, Barcz E, et al. Increased levels of human neutrophil peptides 1, 2, and 3 in peritoneal fluid of patients with endometriosis: association with neutrophils, T cells and IL-8. J Reprod Immunol 2011;91(1-2):64-70
275. Li MQ, Luo XZ, Meng YH, et al. CXCL8 enhances proliferation and growth and reduces apoptosis in endometrial stromal cells in an autocrine manner via a CXCR1-triggered PTEN/AKT signal pathway. Hum Reprod 2012;27(7):2107-16
276. Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 2004;101(32):11791-6
277. Chapman RW, Minnicozzi M, Celly CS, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322(2):486-93
278. Gonsiorek W, Fan X, Hesk D, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 2007;322(2):477-85
279. Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002; 161(1):125-34
280. Tabrizi M, Wang B, Lu H, et al. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases. Inflamm Allergy Drug Targets 2010;9(4): 229-37
281. Skov L, Beurskens FJ, Zachariae CO, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 2008;181(1):669-79
282. Adage T, Piccinini AM, Falsone A, et al. Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans. Br J Pharmacol 2012;167(6):1195-205